Meticulous Research®—a leading market research company, published a research report titled, ‘Europe NGS Automation Market by Product (Platform, Consumables), Sequencing Type (Whole Genome, Exome, Targeted), Application (Drug Discovery, Diagnostics), End User (Hospitals, Diagnostic Laboratories, Pharmaceutical, Academic) - Forecast to 2030.’
According to this latest publication from Meticulous Research®, the NGS automation market in Europe is projected to reach $380.4 million by 2030, at a CAGR of 13.4% from 2023 to 2030. The growth of this market is driven by factors such as the increasing R&D activities in the life sciences industry, the growing demand for NGS automation in laboratories, and the increasing prevalence of chronic diseases such as cancer.
In addition, the increasing applications of next-generation sequencing and the rising number of collaborations between companies to develop library preparation protocols are expected to provide significant growth opportunities for this market. However, the high cost of automation workstations is expected to hamper the adoption of NGS automation solutions and restrain the growth of this market. In addition, factors such as regulatory & standardization concerns in diagnostic testing and the requirement of high-skilled personnel for operating automation software are the major challenges to the growth of this market.
The key players operating in the NGS automation market in Europe are Agilent Technologies, Inc. (U.S.), Danaher Corporation (U.S.), Eppendorf AG (Germany), Hamilton Company (U.S.), PerkinElmer, Inc. (U.S.), Tecan Group Ltd. (Switzerland), PRIMADAG SAS (France), BRAND GMBH + CO KG (Germany), Hudson Robotics (U.S.), SPT Labtech (U.K.), Thermo Fisher Scientific Inc. (U.S.), and F. Hoffmann-La Roche AG (Switzerland).
Europe NGS Automation Market: Future Outlook
The Europe NGS automation market is segmented by product, application, sequencing type, and end user. The study also evaluates industry competitors and analyzes the market at the country level.
In 2023, based on product, the workstation/robotic platform segment is estimated to account for the largest share of the NGS automation market. The large share of this segment is attributed to factors such as the increasing demand for NGS automation solutions in laboratories and the benefits of NGS automation during library preparation compared to manual processes.
In 2023, based on application, the clinical diagnostic segment is slated to register the highest growth rate during the forecast period. The high growth of this segment is attributed to the increasing adoption of NGS by diagnostic laboratories to improve their capabilities in diagnosing rare genetic abnormalities, performing genetic profiling for precision oncology, and detecting pathogens in infectious diseases.
In 2023, based on sequencing type, the whole genome sequencing segment is expected to account for the largest share of this market. The large market share of this segment is attributed to the high demand for NGS automation solutions for WGS to reduce per sample costs.
In 2023, based on end user, the pharmaceutical & biotechnology companies segment is poised to command the largest share of this market. The large share of this segment is attributed to the increasing R&D expenditure by pharmaceutical and biotechnology companies and the rising demand for new drug development and discovery. Additionally, the financial capability of pharmaceutical & biotechnology companies to acquire highly sophisticated NGS automation workstations boosts the growth of this segment.
Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5644
Key questions answered in the report:
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Dental Practice Management Software Market Worth $ 3.11 Billion by 2029Read More